At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVAX Novavax
Post-Market Trading 11-21 19:13:17 EST
8.04
-0.02
-0.25%
盘后8.06
+0.02+0.25%
19:04 EST
High8.34
Low7.96
Vol3.15M
Open8.00
D1 Closing8.06
Amplitude4.78%
Mkt Cap1.29B
Tradable Cap1.15B
Total Shares160.18M
T/O25.63M
T/O Rate2.20%
Tradable Shares143.39M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Novavax Inc. Stock Underperforms Thursday When Compared To Competitors
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.